EVALUATION OF ANTITUMOR EFFICACY OF ESTRAZIN IN RAT PROSTATIC ADENOCARCINOMA
Therapeutic effect of estrazin was evaluated on transplantable R3327-H Dunning rat prostatic adenocarcinoma. Delayed and prolonged antitumor action of estrazin has been demonstrated with maximum inhibition of tumor growth being attained two month after cessation of such a treatment. Inhibition of tumor growth at a dose of 100 mg/kg has amounted to 82%. Therapeutic effect of esrtazin exceeded that of both estracyt and flutamide.
No Comments » Add comments